Literature DB >> 24056893

Is there a role for bevacizumab in the treatment of glioblastoma?

Andrew S Chi1, Marc C Chamberlain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24056893      PMCID： PMC3805148          DOI： 10.1634/theoncologist.2013-0296

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.

Authors:  Kathryn M Field; John Simes; Anna K Nowak; Lawrence Cher; Helen Wheeler; Elizabeth J Hovey; Christopher S B Brown; Elizabeth H Barnes; Kate Sawkins; Ann Livingstone; Ron Freilich; Pramit M Phal; Greg Fitt; Mark A Rosenthal
Journal:  Neuro Oncol       Date:  2015-06-30       Impact factor: 12.300

2.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

3.  Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

Authors:  Walid S Kamoun; Carsten D Ley; Christian T Farrar; Annique M Duyverman; Johanna Lahdenranta; Delphine A Lacorre; Tracy T Batchelor; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Dai Fukumura; A Gregory Sorensen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2009-03-30       Impact factor: 44.544

4.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

5.  Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.

Authors:  Emil Lou; Katherine B Peters; Ashley L Sumrall; Annick Desjardins; David A Reardon; Eric S Lipp; James E Herndon; April Coan; Leighann Bailey; Scott Turner; Henry S Friedman; James J Vredenburgh
Journal:  Cancer Med       Date:  2013-01-24       Impact factor: 4.452
  5 in total
  3 in total

Review 1.  Practical management of bevacizumab-related toxicities in glioblastoma.

Authors:  Alba A Brandes; Marco Bartolotti; Alicia Tosoni; Rosalba Poggi; Enrico Franceschi
Journal:  Oncologist       Date:  2015-01-07

2.  Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial.

Authors:  Orin Bloch; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2014-04-10       Impact factor: 12.300

Review 3.  Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

Authors:  Giuseppe Aprile; Marta Bonotto; Elena Ongaro; Carmelo Pozzo; Francesco Giuliani
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.